Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bill Gates: Vaccines have nanoparticles
https://rumble.com/ve0boj-bill-gates-vaccines-have-nanoparticles.html
FDA asks for 55 years to complete FOIA request on Pfizer's COVID-19 vaccine. Hungry for details on Pfizer's COVID-19 vaccine? Just file a Freedom of Information Act (FOIA) request and wait until the U.S. tricentennial in 2076. That's the schedule the FDA proposed in documents filed in a U.S. District Court this week.
https://www.fiercepharma.com/pharma/fda-requests-55-years-to-complete-foia-request-pfizer-s-covid-19-vaccine
Where do the lipid nanoparticles collect???
https://rumble.com/vipvwl-pfizer-data-reveal-where-do-the-lipid-nanoparticles-collect-robert-malone-s.html
Xenobots are stem cells from frog embryos
https://rumble.com/vl57cd-putting-all-kinds-of-nano-technology-in-people-part-3.html
Why is the US gov pushing the vaccines sheet???
https://rumble.com/vq6w9z-steve-kirsch-warns-of-incomprehensible-conspiracy-among-government.html
THE NEUROPEPTIDE VIP: DIRECT EFFECTS ON IMMUNE CELLS AND INVOLVEMENT IN INFLAMMATORY AND AUTOIMMUNE DISEASES
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484298/
The global t-cell therapy market size was estimated at USD 4.6 billion in 2020 and is expected to reach USD 6.4 billion in 2020.
https://www.grandviewresearch.com/industry-analysis/t-cell-therapy-market
The global autoimmune disease therapeutics market was valued at $109,833 million in 2017, and is projected to reach $153,320 million by 2025, registering a CAGR of 4.2% from 2018 to 2025. An autoimmune disease causes the immune system to destroy its own body tissue.
https://www.alliedmarketresearch.com/autoimmune-disease-therapeutics-market
Vasoactive intestinal peptide (VIP) is a neuropeptide that is produced by the lymphoid cells and plays a major role in immunological functions for controlling the homeostasis of the immune system. VIP has been identified as a potent anti-inflammatory factor, in boosting both innate and adaptive immunity. Since December 2019, SARS-Cov-2 was found responsible for the disease COVID-19 which has spread worldwide. No specific therapies or 100% effective vaccines are yet available for the treatment of COVID-19. Drug repositioning may offer a strategy and several drugs have been repurposed, including lopinavir/ritonavir, remdesivir, favipiravir, and tocilizumab. This paper describes the main pharmacological properties of synthetic VIP drug (Aviptadil) which is now under clinical trials. A patented formulation of vasoactive intestinal polypeptide (VIP), named RLF-100 (Aviptadil), was developed and finally got approved for human trials by FDA in 2001 and in European medicines agency in 2005. It was awarded Orphan Drug Designation in 2001 by the US FDA for the treatment of acute respiratory distress syndrome and for the treatment of pulmonary arterial hypertension in 2005. Investigational new drug (IND) licenses for human trials of Aviptadil was guaranteed by both the US FDA and EMEA. Preliminary clinical trials seem to support Aviptadil’s benefit. However, such drugs like Aviptadil in COVID-19 patients have peculiar safety profiles. Thus, adequate clinical trials are necessary for these compounds. ~ November 30, 2021
https://link.springer.com/article/10.1007/s11356-021-17824-5
Dr. Varawalla will join Relief from Atlantic Healthcare plc, a specialist pharmaceutical company with late-stage clinical assets for inflammatory bowel disease and gastrointestinal dysmotility in rare diseases, where she served as Chief Medical Officer and Head of Clinical Development. Before that, Dr. Varawalla was Managing Director of Clinstrat Ltd, a life science and healthcare business consultancy, where, among other projects, she worked with private equity firms to develop the investment thesis and business plan for the buy-out of BTG plc's specialty pharmaceutical business unit, valued at approximately $1 billion. Before that, Dr. Varawalla was Senior Vice President and Head of Clinical Development at BTG International plc, where she led a global team responsible for clinical development of the company's product portfolio across both pharmaceutical and medical device business units before it was acquired by Boston Scientific for $4.4 billion in 2019.
https://www.wsj.com/articles/relief-therapeutics-announces-executive-changes-01638253834
The pathogenesis of inflammatory bowel syndrome (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC) is poorly understood. However, an inflammatory component is a common hallmark. It has been suggested that CD principally involves Th1 and/or Th17 cells, while UC is considered to be more Th2 driven. Because vasoactive intestinal peptide (VIP) has emerged in the last decade as a putative candidate for the treatment of inflammatory diseases with a Th1 component, it may as well serve as a therapeutic target in CD. In addition, experiments using mice deficient in VIP or its receptors have revealed that the endogenously-produced VIP may participate in the regulation of immunity. The aim of the present review is to summarize the quite considerable array of data which suggests that the VIP-receptor system plays a key role in modulating multiple molecular and cellular players involved in IBD.
https://pubmed.ncbi.nlm.nih.gov/23094828/
The global Crohn's disease therapeutics market size was estimated at USD 3.8 billion in 2016 and is expected to register a CAGR of 2.4% from 2017 to 2025.
https://www.grandviewresearch.com/press-release/global-crohns-disease-therapeutics-market
The treatment of UC includes traditional therapies such as drugs made of tumor necrosis factor (TNF) inhibitors and small molecule. The global ulcerative colitis market accounted for $4,785 million in 2016 and is expected to reach $7,455 million by 2023, registering a CAGR of 6.5% from 2017 to 2023.
https://www.alliedmarketresearch.com/ulcerative-colitis-market
The global inflammatory bowel disease treatment market size is expected to reach USD 27.8 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 4.8% from 2021 to 2028.
https://www.grandviewresearch.com/press-release/global-inflammatory-bowel-disease-ibd-treatment-market
On the RLFTY pricing.
Interesting move by Relief and, again, one that looks sure footed for me.
150 x SIX pricing is about 9 Swiss Francs, or US $9.70. JP Morgan priced it such that after the first day's fall it would go around $9.70. That's the trivial part.
What I like is setting the ADR quantity at 150. This automatically gives them a share price above $5. US $5 or below is penny share range and a lot of institutions, particularly pension funds, will simply not touch penny shares. Their computer screens will have a default filter that does not even show them.
With the ADR quantity at 150 Relief have gone for maximum visibility. It makes no difference at the moment because we have nothing to show, but when APR's Q4 financial results add to our bottom line and when our various event targets come through then that visibility will be primordial.
~ IlkaS, Y@h00 RLFTF finance conversations
FC
17 hours ago
$NRXP conversation
It's very likely that NRx will be responsible for worldwide commercialization operations in covid play. $RLFTF will sit back and enjoy its 50% split and focus its Aviptadil resources on Sarcoidosis. It's a speculation on my part. But one can't help thinking along this direction with the recent manufacturing and trial development especially in the EU region.
~ FC, Y@h00 RLFTF finance conversations
REPLIES:
Chris
Chris
2 hours ago
@FC a request for invoices and budget breakdown are not big asks…especially if you've signed a CA that voids you of all financial risk…not providing something as basic as invoices or budgets is a MASSIVE red flag, every company on the plant would have stopped funding
Petersen
Petersen
3 hours ago
@FC No whining here fella. I just can’t believe how deluded you are.
FC
FC
12 hours ago
@Petersen at the most critical point of the project, Relief started to play invoice/audit tactics because Ram bailed on the risk involved. I've shown in multiple posts that NeuroRx's charge was nothing out of ordinary for clinical development. It was actually on the lower end. Also for inhaled, there were no invoice per sei at that time. Just you in or not? NeuroRx had to raised its own funding for that. Inhaled project was delayed for 6 months. I am not sure why weren't you angry if you were really for covid play? Thank God funding is no longer on the critical path. If you are not investing here, you have no contribution to this funding process. What are you whining for?
Petersen
Petersen
12 hours ago
@FC So the absolute rebuttal of your argument “doesn’t matter”. That’s very rational of you.
FC
FC
14 hours ago
@Petersen it doesn't matter anymore. Does NRx look like they need Relief funding now? Relief abandoned covid play at the most critical time by holding funding and not fund the inhaled project. We all suffer from that. Ram gets a second chance now during meditation process to commit or pass. No more wait and see gamit anymore
stockparty
stockparty
15 hours ago
@FC ty for calling out the flush
Petersen
Petersen
15 hours ago
@FC No invoices = No funding
stockparty
stockparty
15 hours ago
It's possible but seemingly unlikely given the progress made thus far. Interesting that stocktwits message board (listed on yahoo ADMP) mentions Zyesami as being a victim of a conspiracy. Given the piggyback clause it's a little harder to believe. One thing is for sure if you are part of the Javitt family you don't have to make your roti by hand anymore.
FC
FC
15 hours ago
@12345 who #$%$ abandoned the covid play at the most critical time?
Alexander
Alexander
15 hours ago
I agree
12345
12345
16 hours ago
@FC don?t forget all the #$%$ off shareholders that will be lingering out there. i would sleep with one eye open
FC
FC
16 hours ago
@Franz Relief doesn't have any operation resources - it signed contracts with two European partners one year ago and we never heard back anything, zero. So we shall see.
Franz
Franz
16 hours ago
You say #$%$ as usual.Go on ROW or EU and you will be well received.Take this lawsuit, go bankrupt, and close this mouth. Or surrender. Your call. Muted.
FC
FC
17 hours ago
The RLF-100 formulation issue runs deep. It looks like it not only has the stability and manufacturability issue, it might also have the potency issue. That's one of main reasons why Ram wasn't fully committed and why he went for AdVita. It would take ages for Relief to set up manufacturing in EU and ROW even if NRx/Nephron IP gets shared. The best arrangement for both is for NRx to handle the operations and they split the profit. Let's see how it plays out come Jan.
(Old) James
9 hours ago
$RLFTF conversation
Can anyone comment as to WHY Ram chose this timing to launch the ADR trading units? I expected it to happen at the beginning of a long move up in SP, with multiple news and PR developments - so the ADR starts with a track record of moving up. It may work that way, perhaps only because we hit rock bottom (???) and go up from here. We don't expect big catalyst events in the next 6 - 8 weeks, minimum, so the timing is unclear. My guess: the ADR and Nasdaq trading will already be in place if and when good news begins to roll.
Any other ideas?
~ (Old) James, Y@h00 RLFTF finance conversations
REPLIES:
IlkaS
IlkaS
2 hours ago
You want to be on Nasdaq BEFORE the much better news come, as simple as that, and it takes time to uplist through the various ADR levels, and eventually to Nasdaq.
The stated timing would bring Nasdaq listing just before Advita's ARDS first test results and APR's Sentinox Phase 3 results.
For me it all makes sense and I am impressed at the speed they turn things around : registration for ADRs on the 3rd, Live on the 18th !
Ilka
B II
B II
2 hours ago
I believe unlike a stock reverse split, ADR gives them more flexibility on the ratio, so if in the future we rise, they can change the 150 ratio.
But more importantly, being accessible through ADR, we access to more stock buyers which is fundamental to help the stock price rise.
TheGuyOnTheCouch
TheGuyOnTheCouch
2 hours ago
They expect them to be available H1 2022. A lot of studies currently going, an expanding product line, revenue, access by a wider variety of institutional investors, increased legitimacy... I can think of a few things.
Chris
Chris
4 hours ago
Probably because you don’t snap your finger and make an ADR happen at the most convenient time possible?
Joey
Joey
5 hours ago
I definitely agree with you about having everything already in place for when things get hot next year after approval. I also agree with @wong that it was all part of the plan and we're just moving right along according to how the planned their different earmarks. Besides those two reasons, there are a few more; however, I unfortunately can't really express them to much here because of word limits:
3. This first step of consolidation also helps them to see what losses they need to take as tax writes offs. It's a dream having 2 different exchanges where you can withdraw from one , exchange currency and invest in the other (possibly w/o penalty of a wash rule all the while still getting the tax write off for the losses!)
4. Arbitration! And for those who may be wondering, yes arbitrationary gains are absolutely legal! I do this with my Chilean stock account often. The USD:CLP conversion rate was 700 earlier this year...now it's at CLP 800!! In response, I've cashed out of my Chilean stock accts for my investments in AKOA, LTMAQ, and CCU for the year.
Now let's say that the stock prices for all three of these stocks was the exact same in January as it is right now, and let's say that I have the same number of shares in January as now also. The difference in earnings between me cashing out of the stocks in January versus now is that I made 450k CLP more now because of arbitration, or the inflated USD:CLP exchange rate! Thats a whole weeks stay for us on Easter Island, Chile just because of the timing I chose to cash out the long-term exact same #shares for the exact same stock price!
The Conversion rates between the CHF, USD, and EUR are much better now than they were at the beginning of the year and than they will be in H1 2022 according to some forecasts. This is all just IMHO of course, but it's a viable notion, and one that many investors take advantage of completely!
5. Finally, we come to the point that I personally hate to admit. And it's embarrassing. But... You have to admit that there's probably a little competition going on in both camps minds about making their stock outshine the other one's stock. Therefore, they brought it in sooner rather than later to start ramping things up to get going full blast next year ASAP!
If you are on any other platforms like Discord or Facebook, send me a msg and I can explain a little further. Hope that helps!
Bullish
RebelX
RebelX
5 hours ago
goal of listing the ADRs on the New York technology exchange Nasdaq in the first half of next year.
FC
FC
6 hours ago
@Wong of course Ram and Jack the bean counters are best at setting up these financial vehicles. However without advancement in clinical developments, nobody is going anywhere. How is that AMRI factory in Glasgow doing for you? Have they churn out one vial of RLF-100? How is EU Phase 3 doing? EMA must be loving it. Oh, have you paid for the inhaled project yet? It's about time you know.
Wong
Wong
6 hours ago
It was always the plan. They stated multiple times an ADR program would start at the end of 2021. Maybe people are confused because a promise was kept? Unlike all the garbage we have been fed through JJ.
Bullish
FC
FC
7 hours ago
@Mark which inhaler? Oh, the one you didn't pay
Mark
Mark
7 hours ago
I think we get inhaler news very soon and then we start to climb
H. Scott
H. Scott
8 hours ago
Maybe to just keep us stockholders knowing they are still out here and the company is not dead, although we may be dead on news for the next two months. Looks like a smart move.
matthewk
matthewk
8 hours ago
I was a little confused by it also. Maybe just to create a little buzz. And I'm still a little confused how the price is where it is. Isn't it supposed to follow the RLFTF and RLF.SW tickers times 150.
Dan
Dan
8 hours ago
@Hooter86 he has no ideas, he will just make unhelpful and uncalled for comments against oldjames.
BBB
BBB
8 hours ago
@(Old) James, everything you've just talked about agree totally, also from what I read in the article this is just the starting point, and in end of 2021 and in early 2022 will move to ADR 2 then ADR 3 and Nasdaq along with good news, this is the next game plan so we have options with NRX and beyond them if needed, Aviptadil has a great future with or with out Dr.J/NRX,
I've been here this long what's a little longer ,I was always taught keep diversified and never put all your eggs in one basket/RLFTF PROUD
Nicholas
Nicholas
8 hours ago
Timing is everything right? For higher visibility, a larger pool of investors, and coverage by equity analysts. Good news is on the horizon.
I’m with you but I also see powerful actors slow walking us. I thought the experimental vax-sheet would prevent transmissibility——— ZYESAMI/RLF-100/AVIPTADIL can improve our immune system, stop the virus and therefore transmissibility.
https://trialsitenews.com/bill-gates-acknowledges-covid-19-vaccines-not-stopping-viral-transmission-fundamental-premises-questioned/
This is, in part, what we are up against. The CDC, FDA, NIH and government mandates, all acting in concert in support of the vaccine-sheet gravy train.
Demand grows for firms to share vaccine recipes and technology as billionaire pharma bosses convene for ‘Big Pharma Davos’
New figures from the Peoples Vaccine Alliance reveal that the companies behind two of the most successful COVID-19 vaccines —Pfizer, BioNTech and Moderna— are making combined profits of $65,000 every minute. The figures based on the latest company reports are released as CEOs from pharmaceutical industry meet for the annual STAT summit —the equivalent of a ‘Big Pharma Davos’— from 16-18 November.
These companies have sold the majority of doses to rich countries, leaving low-income countries out in the cold. Pfizer and BioNTech have delivered less than one percent of their total vaccine supplies to low-income countries, while Moderna has delivered just 0.2 percent. Meanwhile 98 percent of people in low income countries have not been fully vaccinated.
https://reliefweb.int/report/world/pfizer-biontech-and-moderna-making-1000-profit-every-second-while-world-s-poorest
NONE OF THE MAIN SHAREHOLDERS SOLD!SAME AS MONTHS AGO!FOLLOW THE MONEY!HOLD!
Global Emerging Markets North America, Inc. 1,158,000,000 26.3%
Relief Therapeutics Holding AG 413,815,700 9.38%
BG Consulter GmbH 136,343,167 3.09%
Yves Sagot 75,401,533 1.71%
BlackRock Fund Advisors 22,758,362 0.52%
Credit Suisse Asset Management (Schweiz) AG 22,265,646 0.50%
Ga?l H?dou 16,375,998 0.37%
UBS Asset Management Switzerland AG 13,679,000 0.31%
Z?rcher #$%$onalbank (Investment Management) 12,678,834 0.29%
Michel Dreano 4,333,334 0.098%
~Hans, Y@h00 RLFTF finance conversations
FDA is waiting on data for Zyesami IV. The Zyesami inhaled form would be used to pursue about (5) other lung indications, among them ARDS and COPD.
Exactly, patents of VIP extracted from animals. It is claimed by NRXP that AVIPTADIL (synthetic) generic was used to continue development of Zyesami (TM). Zyesami (tm) in acetate buffer vs RLF-100 in no buffer. Well, if the AVIPTADIL patent holder is RLFTF, what exactly did SUNY license to NRXP or does it matter? Is all this an NRXP stunt to negotiate terms with RLFTF, for further development of Zyesami (tm), all under the assumption they get approval for Zyesami (tm) IV?
Patent US8178489B2
Inventor Gerald BacherDorian Bevec Current Assignee Relief Therapeutics International Sa
https://patents.google.com/patent/US8178489B2/en
Mondobiotech Aviptadil, expired.
https://patents.google.com/patent/WO2006094764A1/en
What did SUNY University license, Sami Said body of work while at SUNY???
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070814/
Patents???
https://patents.justia.com/inventor/sami-i-said
SUNY PATENT POLICY
Binghamton University complies with the State University of New York Patents, Inventions and Copyright Policy (the “Policy”). To read the full Policy, click here.
ROYALTY DISTRIBUTION
The SUNY Policy provides for sharing between the inventor and the University of net royalty income from the licensing of inventions. The policy calls for 45% of the first $100,000 in cumulative net income to be provided to the inventor as personal income, with the percentage becoming 40% thereafter. The remaining net royalties are returned to the President for distribution with the campus on the following basis:
40% of the campus portion of the first $100,000 in net royalty in any given year goes to the inventor's department. Annual net royalty in excess of $100,000 will be made in favor of the President. For the College of Community and Public Affairs, the Decker School of Nursing and the School of Management, the department allotment goes to the dean For non-academic units, the allotment will go to the appropriate Vice President. If a faculty member is associated with an organized research center, half of this allotment shall go to that center.
35% goes to the Vice President for Research to support research and scholarly activities.
25% of the campus portion goes to the Office of Entrepreneurship and Innovation Partnerships in the Division of Research to cover technology transfer activities.
If there are multiple inventors and departments, then the amounts will apply to the combined shares of the recipients. Distribution will be determined by prior agreement as delineated in the new technology disclosure or as equal shares.
https://www.binghamton.edu/research/innovation/technology-transfer/patentpolnroyaltydist.html
Don’t forget the licensor, SUNY University…
"Licensor" means the individual, individuals, entity or entities that offer(s) the Work under the terms of this License. ... The licensor permits others to copy, distribute, display, and perform the work.
https://www.dictionary.com/browse/licensor
And this fine cast of actors——
https://rumble.com/vhpbwf-faucis-boss-and-fauci-drop-new-bombshells-about-covid-19-and-vaccinescovid-.html
Ensovibep from Molecular Partners is out of the game. ACTIV 3 (NCT04501978) interim analysis showed no activity…
We are still here and our ACTIV3b is still recruiting.
~ IG, Y@h00 RLFTF finance conversations
UTILIZE DISPUTE RESOLUTION CLAUSES TO SETTLE ISSUES AMICABLY
Even in the event that a dispute arises, the parties can preemptively agree to strategies to resolve the dispute long before they reach trial or arbitration. During the contract negotiation process, consider requiring that the contracting parties initiate a multi-stage dispute resolution process before any party can initiate a lawsuit or commence arbitration. Known as an escalation clause or multistage dispute resolution clause, this contract provision requires that the parties first negotiate in good faith to try to resolve a dispute amicably before they can initiate proceedings. This opportunity can provide invaluable time to exchange information, renegotiate arrangements that no longer serve the interests of the parties, and avoid rushing to court or arbitration.
https://www.lifescienceleader.com/doc/how-to-navigate-pharma-collaboration-and-licensing-agreements-0001
Updated November 11, 2021
NRx was the first to formulate aviptadil for human intravenous and inhaled use under the "Good Manufacturing Practices" standards in 2020. Zyesami (Aviptadil) (RLF-100) COVID-19 therapeutic has received orphan drug designation from the U.S. Food and Drug Administration (FDA) in acute respiratory distress syndrome, chronic lung diseases, and the treatment of sarcoidosis. In June 2020, the FDA awarded Fast Track Designation to NRx for the use of aviptadil for the treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome associated with COVID-19.
Additionally, the U.S. FDA has approved an expanded access protocol for the use of RLF-100 in patients with Critical COVID-19 and Respiratory Failure. The purpose of this expanded access program is to serve patients with a life-threatening need who don't qualify for or cannot access the FDA phase 2/3 clinical trials currently underway. Patients will be treated with 12-hour infusions of RLF-100 at ascending doses of 50/100/150 pmol/kg/hr on three successive days. Those respiratory conditions include Acute Respiratory Distress Syndrome, Chronic Obstructive Pulmonary Disease, acute smoke inhalation, sarcoidosis, and checkpoint inhibitor pneumonitis.
https://www.precisionvaccinations.com/vaccines/zyesami-aviptadil-therapeutic
https://rumble.com/vohf25-suspended-medical-ethics-prof.-aaron-kheriaty-on-vaccine-coercion-risks-and.html
My late uncle's research is being used to help treat COVID patients
Family pride meets university research, patent licensing and a meaningful trademark.
My uncle, Dr. Sami I. Said, MD, was a researcher and distinguished professor. He finished his career at Stony Brook University in New York after serving as Chief of Pulmonary and Critical Care. After training as a medical doctor in Egypt, he spent time at Johns Hopkins University, the Karolinska Institute in Sweden, and worked in Oklahoma and many Veterans Administration hospitals in the United States.
Research & Memories
In 1970, he discovered Vasoactive Intestinal Peptide (VIP). He continued his research on VIP and its applications for the rest of his career, collaborating with others around the world.
I remember many American Thanksgiving and Christmas celebrations with Uncle Sami, since he traveled from the US to spend both of those holidays with us in Ottawa almost every year. Like in the photo at the top of this article, Uncle Sami would recline and tune in to important NFL games, while multitasking and reviewing scientific papers, preparing grant applications, or reading the New York Times.
A fond memory was when our family joined him at the American Thoracic Society (ATS) conference in Toronto in 2000, where he was named the "Amberson Lecturer" for his major contributions to pulmonary physiology and pharmacology.
He never retired, just like his father (my grandfather, a Coptic Evangelical Christian minister). He was an inventor and had 8 US patents (which I found cool, as a patent agent), and was still working on a potential new patent shortly before he passed away.
VIP in COVID treatment
Now his patented research in VIP is being licensed and used for treating COVID patients. I'm so proud. (While there has been a lot of focus on vaccines, treatments for people who have COVID are also very important.)
Last month, US-based NeuroRx announced some promising results from the Phase 2b/3 trial of ZYESAMI™ (aviptadil, previously RLF-100™) for the treatment of Respiratory Failure in critically ill patients with Covid-19. According to the press release, at 28 days, patients treated with ZYESAMI™ "demonstrate 35% higher likelihood of recovery from respiratory failure with continued survival...In tertiary care hospitals, ZYESAMI-treated patients were 46% more likely to recover and return home before day 28".
Also from the press release (emphasis added):
"COVID-19-related respiratory failure is caused by selective infection of the ATII cell by the SARS-CoV-2 virus. VIP is shown to block Coronavirus replication in the ATII cell, block cytokine synthesis, block viral-induced cell death (cytopathy), and upregulate surfactant production. To our knowledge, other than ZYESAMI™, no currently proposed treatments for Covid-19 specifically target these vulnerable Type II cells. Recent laboratory findings suggest that VIP directly interferes with the spike protein complex of the SARS-CoV-2 virus."
A couple of interesting personal notes about the trademark:
The trademark includes my Uncle's name "SAMI";
If you pronounce "ZYESAMI" in Arabic (my Uncle's native tongue), it means "like Sami". This is so fitting for a treatment built on decades of collaborative research that is being used to care for patients suffering from COVID-19 in the current global pandemic.
In fact, in an earlier MedPage Today article, a former colleague of Uncle Sami's put it eloquently when speaking about this use of his research:
"I am cheering for Sami Said, because if somewhere out there, he knew his drug could block the progression of COVID, there wouldn't be a happier man in the world"
Conclusion
Uncle Sami was a doctor and an educator, a gentleman and a family man. He really would be so pleased to see this new life-saving use of his life-long research.
But he would also be humble about it, and emphasize everyone else's contributions. And that would be classic Uncle Sami, and would make me even more proud of him.
https://www.linkedin.com/pulse/my-late-uncles-research-being-used-help-treat-covid-patients-behmann
https://rumble.com/vio409-virus-origin-investigation-blocked-by-u.s.-elites-politicians-experts-media.html
THIS PETITION
https://savepeptides.org/
DO PEPTIDES NEED PROTECTION???
https://rumble.com/vlxcbm-ep-81-peptides-helping-to-heal-ft.-dr.-edwin-lee.html
THEN SIGN THE PETITION
https://rumble.com/vlxcbm-ep-81-peptides-helping-to-heal-ft.-dr.-edwin-lee.html
"Don't wait": WHO urges U.S. to pay attention as surging COVID cases flood Europe's hospitals again
London — The coronavirus has been resurging across Europe, including in some places where it was thought to be well under control. A top world health official tells CBS News the trend shows that success today does not necessarily mean success tomorrow, and the United States should pay close attention.
Europe has seen a jump of more than 50% in new coronavirus cases over the last month, and the World Health Organization has warned the continent could see another half of a million deaths by February. CBS News senior foreign correspondent Charlie D'Agata spoke with the top official ringing those alarm bells, who told him there's "grave concern" as Europe is once again under siege by COVID-19.
U.S. lifts most COVID-linked bans on travellers from abroad
"If you look at the last four weeks, the hospitalizations have doubled," Dr. Hans Kluge, the World Health Organization's Regional Director for Europe, told CBS News.
He said vaccination uptake has plateaued in some parts of Europe and, "at the same time, there's a relaxation of the public health and social measures, which is a cocktail for what we see: a fourth wave."
Kluge called Europe "the epicenter" of a new global COVID-19 outbreak, fuelled by the highly transmissible Delta variant of the virus.
While case rates are up across the continent, European countries with higher vaccination uptake appear to be staving off a major new wave of severe COVID-19 illness, but in some Eastern European nations, the daily mortality rate is surging.
Portugal has one of the highest vaccination rates in the world, for instance, whereas Romania has one of the lowest in Europe — and one the highest death rates on the globe.
On Monday, Germany's daily infection rate hit its highest recorded level since the pandemic began.
"Vaccines are a game changer," said Kluge. But alone, they are "not enough."
"We need to keep pressure on the virus, not surrendering on masks, the hand-washing, indoor ventilation — particularly in the schools," he told D'Agata.
Gottlieb predicts "broad immunity" among U.S. kids
In the U.K., the virus' spread in schools — where face masking and most other anti-virus mandates were dropped from the beginning of this academic year — is being blamed for rising case numbers. The rise, while not mirrored in hospitalizations or deaths, is stoking fear that another lockdown could be looming this winter.
"I think they can see it coming. But it's that fine line between letting people go about their daily lives and also trying to keep people safe," said Toni Watkins as she shopped on London's Oxford Street, acknowledging the difficult calculous the British government and others across Europe are facing.
Kluge told CBS News that Americans should "absolutely" be paying close attention to the situation in Europe right now — and taking lessons from it.
"The basic principle is, if there is a situation where the peak is accelerating, don't wait" to bring back anti-virus measures, and "the earlier, the stricter, the better."
D'Agata asked Kluge what that could mean for the fast-approaching Thanksgiving and Christmas holidays. He said people should celebrate, but safely — trying to keep numbers down when different households mix, and he stressed the need to "vaccinate and ventilate."
First published on November 8, 2021 / 9:51 AM © 2021 CBS Interactive Inc. All Rights Reserved.
~ Ana, Y@h00 RLFTF finance conversations
UNIVERSAL VACCINES ENFORCEMENT
https://rumble.com/vnh8qk-fauci-hhs-officials-discuss-using-new-virus-from-china-to-enforce-universal.html
THE REAL REASON BEHIND GOVERNMENT MANDATES
The sleep aids market size was valued at $49,543 million in 2016, and is estimated to reach $79,851 million by 2023, registering a CAGR of 7.0% from 2017 to 2023.
https://www.alliedmarketresearch.com/sleep-aids-market
Long-haul Lyme and Long-haul COVID-19
What VIP Does
Regulates Cortisol and Circadian Rhythms
VIP is a hormone produced in the hypothalamus of the brain, and it acts on the HPA Axis: the “stress” axis of the hypothalamus, pituitary, and adrenal glands to regulate adrenal hormone production and release. This means everything downstream from the adrenals improves, including cortisol, DHEA (the precursor to sex hormones) and aldosterone, which regulates fluid volume in conjunction with ADH.
Data suggests that VIP also directly stimulates production of the “core” stress hormone too: norepinephrine. For someone in constant fight-or-flight, you might not think this is a good thing—but these people are actually depleted in catecholamines like norepinephrine more often than not, and increasing overall stores of it can be very helpful.
The HPA axis has a strong effect on circadian rhythms, so it helps regulate sleep cycles and melatonin as well.
Improves Digestion
Since out-of-whack cortisol levels lead to a thinned gut lining and a predisposition to food sensitivities, VIP also helps to repair leaky gut. This is also in part because VIP directly increases blood flow to the gut, improves gut motility, and stimulates release of enzymes, stomach acid, and bile in the gut.
Improves Immune Tolerance
Hypersensitive individuals who seem to react poorly to everything know how important this one is. Specifically, this refers to VIP decreasing Th1 autoimmune responses and promoting Th2 (allergic) responses instead, since this is always a trade-off.
But ultimately, VIP lowers most inflammatory cytokines (those second messengers of the immune system that trigger it to jump into action) and encourage production of the T regulatory cells that help promote immune tolerance.
https://www.drlaurendeville.com/articles/vip-for-biotoxin-illness/
The global autoimmune disease therapeutics market was valued at $109,833 million in 2017, and is projected to reach $153,320 million by 2025, registering a CAGR of 4.2% from 2018 to 2025. An autoimmune disease causes the immune system to destroy its own body tissue.
https://www.alliedmarketresearch.com/autoimmune-disease-therapeutics-market
Take a good look at Cassava Sciences SAVA story. RLFTF will rebound like SAVA did.
Sava got a bad report from the FDA and sank to 2.57 a share. Than the FDA, months later, reported great news and sava hit a high 146.00 a share. Looking good, right,? Than a bad actor investment firm reports that the study results were a lie. sava goes down again. months later, the bad actor was found to be wrong. the results were good. Sava rebounds back to a high of 76.00.
The FDA and bad actors are common trouble for pharma, especially small pharma.
Study sava and hold your shares.
~ Fred, Y@h00 RLFTF finance conversations
Money hand over fist in this stock. Anyone buying anything exciting over the weekend with your gains? It was a beautiful setup and an easy trade. Possible to see a little pullback on Monday then looking for a continuation pattern. ?? Beautiful… congratulations to all on such a remarkably successful week!
~ The Roc, Y@h00 RLFTF finance conversations
AVIPTADIL is the therapy for the long haul population!
https://rumble.com/viww7l-the-long-haul-covid-fight-inside-a-comprehensive-covid-center.html
Or they may be in search of another collaboration agreement.
I read “the swordsman” answer to your question. Big PHARMA in Europe may be looking (speculation) for licenses to develop AVIPTADIL for indications that could, for example, be treated with gene therapy and/or immunotherapies to conquer cancer.
Research by Dr. Ritchie Shoemaker has shown VIP corrects gene activation abnormalities in CIRS caused by exposure to water damaged buildings. Their research showed changes in genes controlling both ribosomes and mitochondria. Dr. Shoemaker has made testing for gene activity or suppression in relation to CIRS (ProgeneDx) availble at www.survivingmold.com.
Gene ID: 7432, updated on 29-Oct-2014, Also Known As: PHM27 The protein encoded by this gene (VIP) belongs to the glucagon family. Alternative splicing occurs at this locus and two transcript variants encoding distinct isoforms have been identified. GENE ID LINK
https://youarethehealer.org/mold-and-toxins/moldy-people/testing-for-mold-illness/vasoactive-intestinal-peptide/
Yeeee-haaah!! Thank you for that!!
PERHAPS BIG PHARMA IS INTERESTED IN BUYING SOME LICENSES, YES??? NO???
https://www.gesundheitsindustrie-bw.de/en/article/news/inhalation-intestinal-hormone-vip-helps-against-immunotherapy-induced-pneumonia
IS RT WAITING FOR FRUIT TO FALL OFF THE TREE???
Relief Therapeutics and AdVita Lifescience are set to enrol the first patient in a Phase II trial of an inhaled formulation of the former’s lead compound, RLF-100 (aviptadil), for preventing Covid-19-related acute respiratory distress syndrome (ARDS).
Relief Therapeutics and AdVita Lifescience are set to enrol the first patient in a Phase II trial of an inhaled formulation of the former’s lead compound, RLF-100 (aviptadil), for preventing Covid-19-related acute respiratory distress syndrome (ARDS).
A synthetic form of a vasoactive intestinal peptide, aviptadil is being developed by NeuroRx as Zyesami in partnership with Relief Therapeutics.
Named ‘Inhaled Aviptadil for the Prevention of COVID-19 Related ARDS’, the randomised, double-blind, placebo-controlled trial will be carried out at various clinical sites in Switzerland.
https://www.clinicaltrialsarena.com/news/relief-advita-ards-prevention/
How SARS-CoV-2 in American deer could alter the course of the global pandemic
https://www.npr.org/sections/goatsandsoda/2021/11/10/1054224204/how-sars-cov-2-in-american-deer-could-alter-the-course-of-the-global-pandemic
ARE WE A SHOE IN???
Google the UK's Innovative Licensing and Access Pathway , ILAP , ~5 months for drug approval ! I emailed RLF IR about it , you should too !
~ Martin, Y@h00 RLFTF finance conversations
————————->
Overview. The Innovative Licensing and Access Pathway ( ILAP ) aims to accelerate the time to market, facilitating patient access to medicines. ... The ILAP is open to both commercial and non-commercial developers of medicines (UK based and or global).
https://www.gov.uk/guidance/innovative-licensing-and-access-pathway
NRx Pharmaceuticals Receives US Food and Drug Administration Review of ZYESAMI® (aviptadil) Manufacturing Information
https://finance.yahoo.com/news/nrx-pharmaceuticals-receives-us-food-125400282.html
Made up of two business units – Novartis Pharmaceuticals, which includes Novartis Gene Therapies, and Novartis Oncology – our Innovative Medicines division commercializes innovative patented medicines to enhance health outcomes for patients and healthcare professionals. ~ About Novartis, Novartis dot com
Novartis seems to need money. Would be about the right amount if they want to buy us...
"Novartis sells its Roche stake to Roche for $20.7 bln"
~ Dr Dip Fisher, Y@h00 RLFTF finance conversations
I’m so incredibly stoked about the future of Aviptadil.
~ Mathieu, Y@h00 RLFTF finance conversations
https://www.scendea.com/fast-track-designation-and-breakthrough-therapy-designation
FDA did not reject the EUA for safety or ineffectiveness. It said the data from only 135 patients not enough to conclude anything. Rolling review ongoing. Additional data to be submitted. NIH trial could end any day upon a finding of clear superior efficacy of Aviptadil versus Remdesivir. Not clear on why such negativity. Far from over. Not just Covid but for so many other respiratory lung diseases. Either you believe it works like those whose lives it has saved, or you think they made up stories. You decide. Great time to load up even more.
~ Mathieu, Y@h00 RLFTF finance conversations
——————————————
Reply
My concern is with the FDA's approval of the Trial Plan. They upwardly revised the pln to 196 knowing full well that would be on a 2:1 treatment/placebo ratio thereby only rendering 131 "treated" (with aviptadil) patients.
Per Nrx's June 25th 2021 S-1 filing, p.75:
"The Intravenous Trial was originally conceived by us and approved by the FDA as a 28-day clinical trial."
"In December 2020, prior to unblinding, we recognized that one-third of the patients participating in the trial were still in the ICU at 28 days and notified the FDA of the need for a 60-day endpoint. The FDA amended its guidance to assess 196 participants to a primary endpoint at 60 days prior to patient-level unblinding."
"The FDA’s February 2021 guidance included a mandate to consider treatment site effects."
https://www.sec.gov/Archives/edgar/data/1719406/000119312521200558/d175615ds1.htm#tx175615_12
So instead of owning up to the error in guidance they just dumped it on Nrx & RL.
This is not the first time they did this. Look at this prior post on Reddit:
"Is a trial of 196 patients enough? Merck previously tried for an EUA for their drug due to results based off a trial with around 200 patients but the FDA decided to hold off until they received more data."
https://www.reddit.com/r/COVID19/comments/npttvu/nrx_pharmaceuticals_announces_positive_results/
~ Zorro, Y@h00 RLFTF finance conversations